Información de Personalis Inc, dividendo de Personalis Inc, actividades de los accionistas y más

Más Datos de Personalis Inc Compañía

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Información de Personalis Inc



Símbolo de cotizaciónPSNL

Nombre de la empresaPersonalis Inc

Fecha de salida a bolsaJun 20, 2019

Director ejecutivoMr. Christopher M. (Chris) Hall

Número de empleados229

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 20

Dirección6600 Dumbarton Circle

CiudadFREMONT

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal94555

Teléfono16507521300

Sitio Webhttps://www.personalis.com/

Símbolo de cotizaciónPSNL

Fecha de salida a bolsaJun 20, 2019

Director ejecutivoMr. Christopher M. (Chris) Hall

Ejecutivos de Personalis Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Aaron Tachibana

Chief Financial Officer, Chief Operating Officer

163.21K

-0.39%

Dr. Richard Chen, M.D.

Executive Vice President - Research and Development, Chief Medical Officer

120.75K

-0.37%

Ms. Lonnie Shoff

Independent Director

20.63K

+99.99%

Ms. Karin Eastham, CPA

Independent Chairman of the Board

13.51K

--

Mr. Stephen Moore

Senior Vice President, Chief Legal Officer, and Corporate Secretary

--

Mr. Woodrow A. (Woody) Myers, Jr., M.D.

Independent Director

--

Ms. Olivia K. Bloom, CPA

Independent Director

--

Mr. A. Blaine Bowman

Independent Director

--

Mr. Christopher M. (Chris) Hall

President, Chief Executive Officer, Director

--

Dr. Kenneth Jon (Ken) Widder, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Aaron Tachibana

Chief Financial Officer, Chief Operating Officer

163.21K

-0.39%

Dr. Richard Chen, M.D.

Executive Vice President - Research and Development, Chief Medical Officer

120.75K

-0.37%

Ms. Lonnie Shoff

Independent Director

20.63K

+99.99%

Ms. Karin Eastham, CPA

Independent Chairman of the Board

13.51K

--

Mr. Stephen Moore

Senior Vice President, Chief Legal Officer, and Corporate Secretary

--

Mr. Woodrow A. (Woody) Myers, Jr., M.D.

Independent Director

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Sin datos

Por regiónUSD

Nombre

Ganancia

Proporción

United States

16.34M

95.00%

Others

860.15K

5.00%

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: mié., 3 de sep

Accionistas

Tipos de accionistas

Accionistas

Proporción

Merck & Co Inc

15.82%

Tempus AI Inc

14.32%

Lightspeed Venture Partners

9.19%

ARK Investment Management LLC

8.00%

BlackRock Institutional Trust Company, N.A.

4.27%

Otro

48.39%

Accionistas

Proporción

Merck & Co Inc

15.82%

Tempus AI Inc

14.32%

Lightspeed Venture Partners

9.19%

ARK Investment Management LLC

8.00%

BlackRock Institutional Trust Company, N.A.

4.27%

Otro

48.39%

Tipos de accionistas

Accionistas

Proporción

Corporation

30.14%

Investment Advisor

22.29%

Investment Advisor/Hedge Fund

12.99%

Venture Capital

9.19%

Private Equity

3.24%

Hedge Fund

2.70%

Research Firm

1.55%

Individual Investor

1.14%

Pension Fund

0.60%

Otro

16.17%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

235

47.23M

53.19%

-84.21K

2025Q2

227

69.99M

79.03%

+1.80M

2025Q1

223

76.78M

86.93%

+10.49M

2024Q4

213

73.54M

83.34%

+21.51M

2024Q3

203

51.51M

73.15%

+1.63M

2024Q2

208

30.80M

57.54%

-8.76M

2024Q1

264

31.11M

59.99%

-9.40M

2023Q4

271

31.05M

62.33%

-8.25M

2023Q3

297

34.10M

70.92%

-7.87M

2023Q2

312

35.53M

73.99%

-8.07M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Merck & Co Inc

14.04M

15.84%

--

Jun 30, 2025

Tempus AI Inc

12.72M

14.34%

--

Sep 11, 2025

Lightspeed Venture Partners

8.16M

9.2%

--

Jun 30, 2025

ARK Investment Management LLC

7.11M

8.02%

-80.27K

-1.12%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.80M

4.28%

+2.10M

+123.36%

Jun 30, 2025

The Vanguard Group, Inc.

3.14M

3.54%

+1.85M

+143.07%

Jun 30, 2025

AIGH Capital Management, LLC.

2.79M

3.14%

-194.57K

-6.53%

Jun 30, 2025

abrdn Inc.

1.76M

1.98%

+54.71K

+3.21%

Jun 30, 2025

Blue Water Life Science Advisors, LP.

1.68M

1.89%

+500.90K

+42.62%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.37M

1.54%

+851.42K

+165.59%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

ARK Genomic Revolution ETF

4.51%

Invesco NASDAQ Future Gen 200 ETF

0.65%

Global X Genomics & Biotechnology ETF

0.47%

ProShares Ultra Nasdaq Biotechnology

0.06%

iShares Micro-Cap ETF

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

Avantis US Small Cap Equity ETF

0.04%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Value ETF

0.02%

ProShares UltraPro Russell2000

0.01%

ARK Genomic Revolution ETF

Proporción4.51%

Invesco NASDAQ Future Gen 200 ETF

Proporción0.65%

Global X Genomics & Biotechnology ETF

Proporción0.47%

ProShares Ultra Nasdaq Biotechnology

Proporción0.06%

iShares Micro-Cap ETF

Proporción0.06%

Invesco Nasdaq Biotechnology ETF

Proporción0.06%

Avantis US Small Cap Equity ETF

Proporción0.04%

iShares Biotechnology ETF

Proporción0.03%

iShares Russell 2000 Value ETF

Proporción0.02%

ProShares UltraPro Russell2000

Proporción0.01%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos